ERBB2 and gastric cancer: Another potential therapeutically relevant marker, Her2, which is overexpressed or amplified in a significant subset of gastro-esophageal adenocarcinomas and which is regarded as a predictive marker for anti-Her2 targeted therapy (32), has been shown to be less expressed in EBV-associated GC compared to EBV negative GC (33–36).